An investigation for investors in NYSE:RDY shares over potential securities laws violations by Dr.Reddy’s Laboratories Ltd and certain of its directors and officers was announced.
Investors who purchased shares of Dr.Reddy’s Laboratories Ltd (ADR) (NYSE:RDY), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether certain statements by Dr.Reddy’s Laboratories Ltd regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On November 6, 2015, Dr.Reddy’s Laboratories Ltd (ADR) (NYSE:RDY) issued a statement acknowledging that it has received a warning letter issued by the US FDA dated November 05, 2015 relating to its API manufacturing facilities at Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as Oncology Formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh. Dr.Reddy’s Laboratories Ltd said that this action follows the earlier inspections of these sites by the agency in November 2014, January 2015 and February 2015 respectively. Shares of Dr.Reddy’s Laboratories Ltd (ADR) (NYSE:RDY) declined to as low as $52.31 per share on November 6, 2015.
Those who purchased NYSE:RDY shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego